Asunercept  (Synonyms: APG101; CAN008)

Asunercept (APG101; CAN008) is a soluble CD95-Fc fusion protein targeting CD95L. Asunercept disrupts CD95/CD95L signaling by selectively binding to CD95L. Asunercept can be used in the research of glioblastoma multiforme (GBM), myelodysplastic syndrome (MDS), and graft-versus-host disease (GvHD)^[1][2][3].

Human

CD95L^[1][2][3].

Asunercept (APG101; 0-100 µg/mL; preincubation for 30 min) specifically neutralizes the proapoptotic activity of recombinant CD95L in Jurkat A3 cells^[1].
Asunercept (0.2, 2, 20 µg/mL; 72 h) is capable of interfering with CD95-induced migration/invasion of glioma cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

1450882-18-4

Liquid

Colorless to light yellow

[Asunercept]

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  [FAS (Fas cell surface death receptor, TNFRSF6, tumor necrosis factor receptor (TNFR)superfamily member 6, FAS1, APO-1, CD95)]2-IGHG1 Fc (Fragment constant)

• 
  Immobilized Asunercept can bind Anti-Fas/CD95/TNFRSF6 Antibody. The EC₅₀ for this effect is 38.57 ng/mL.

• [1]. Merz C, et al. Neutralization of the CD95 ligand by APG101 inhibits invasion of glioma cells in vitro. Anticancer Drugs. 2015 Aug;26(7):716-27.  [Content Brief]

  [2]. Krendyukov A, et al. Asunercept as an innovative therapeutic approach for recurrent glioblastoma and other malignancies. Cancer Manag Res. 2019 Sep 2;11:8095-8100.  [Content Brief]

  [3]. Radujkovic A, et al. Clinical Response to the CD95-Ligand Inhibitor Asunercept Is Defined by a Pro-Inflammatory Serum Cytokine Profile. Cancers (Basel). 2020 Dec 8;12(12):3683.  [Content Brief]